Federation of Clinical Immunology Societies Goes South 2021: advanced course on molecular and cellular translational immunology

References

• 1. Federation of Clinical Immunology Societies. About FOCIS – FOCIS. www.focisnet.org/about-focis/
  Google Scholar
• 2. Federation of Clinical Immunology Societies. FCEs – FOCIS. www.focisnet.org/communities/fces/
  Google Scholar
• 3. Millennium Institute on Immunology and Immunotherapy. IMII – Instituto Milenio en Inmunología e Inmunoterapia. www.imii.cl/en/quienes-somos/
  Google Scholar
• 4. Kalergis AM, Anegon I, González PA. FOCIS goes south: advances in translational and clinical immunology. Immunotherapy 9(10), 789–792 (2017).
  CASGoogle Scholar
• 5. Abbas AK, Lichtman AH, Pillai S, Baker DL. Cellular and Molecular Immunology (10th Edition). Elsevier, PA, USA (2022).
  Google Scholar
• 6. Murphy KM, Weaver C. Janeway's Immunobiology (9th Edition). Garland Science, NY, USA (2017).
  Google Scholar
• 7. Picarda E, Bézie S, Boucault L et al. Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells. JCI Insight 2(3), e90088 (2017).
  MedlineGoogle Scholar
• 8. Boucault L, Lopez Robles M-D, Thiolat A et al. Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease. Blood Adv. 4(11), 2501–2515 (2020).
  Medline CASGoogle Scholar
• 9. Besnard M, Sérazin C, Ossart J et al. Anti-CD45RC antibody immunotherapy for the treatment of the auto-immune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) syndrome. J. Clin. Invest. 132(7), e156507 (2022).
  Medline CASGoogle Scholar
• 10. Roncarolo MG, Gregori S, Bacchetta R, Battaglia M, Gagliani N. The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases. Immunity 49(6), 1004–1019 (2018).
  Medline CASGoogle Scholar
• 11. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75(2), 263–274 (1993).
  Medline CASGoogle Scholar
• 12. Groux H, O'Garra A, Bigler M et al. A CD4⁺ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389(6652), 737–742 (1997).
  Medline CASGoogle Scholar
• 13. Barzaghi F, Amaya Hernandez LC, Neven B et al. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study. J. Allergy Clin. Immunol. 141(3), 1036–1049.e5 (2018)
  MedlineGoogle Scholar
• 14. Bacchetta R, Barzaghi F, Roncarolo M-G. From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation. Ann. NY Acad. Sci. 1417(1), 5–22 (2018).
  Medline CASGoogle Scholar
• 15. Glocker E-O, Kotlarz D, Boztug K et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361(21), 2033–2045 (2009).
  Medline CASGoogle Scholar
• 16. Sato Y, Passerini L, Piening BD et al. Human‐engineered Treg‐like cells suppress FOXP3‐deficient T cells but preserve adaptive immune responses in vivo. Clin. Transl. Immunol. 9(11), e1214 (2020)
  Medline CASGoogle Scholar
• 17. Chabalgoity JA, Dougan G, Mastroeni P, Aspinall RJ. Live bacteria as the basis for immunotherapies against cancer. Expert Rev. Vaccines 1(4), 495–505 (2002).
  Medline CASGoogle Scholar
• 18. Agorio C, Schreiber F, Sheppard M et al. Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. J. Gene Med. 9(5), 416–423 (2007).
  Medline CASGoogle Scholar
• 19. Grille S, Moreno M, Bascuas T et al. Salmonella enterica serovar Typhimurium immunotherapy for B-cell lymphoma induces broad anti-tumour immunity with therapeutic effect. Immunology 143(3), 428–433 (2014).
  Medline CASGoogle Scholar